Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Case-finding strategies in non-alcoholic fatty liver disease
View:
Post by scarlet1967 on Apr 03, 2021 11:19am

Case-finding strategies in non-alcoholic fatty liver disease

Well the summary says it all..
“Among the large population of patients with non-alcoholic fatty liver disease (NAFLD), identifying those with advanced disease remains challenging. Many patients are diagnosed late, following the development of liver-related complications, leading to poor clinical outcomes. Accumulating evidence suggests that using non-invasive tests for liver fibrosis in patients with metabolic risk factors improves the detection of patients in need of specialised management and is cost-effective. Because of the vast number of patients requiring evaluation, the active participation of general practitioners and physicians who manage patients with metabolic disorders, such as diabetologists, is crucial; this calls for the increased awareness of NAFLD beyond liver clinics. Non-invasive case-finding strategies will need to be further validated and generalised for upcoming drug therapies to have the required impact on the worldwide burden of NAFLD.”
https://www.jhep-reports.eu/article/S2589-5559(20)30153-1/fulltext
Comment by Wino115 on Apr 03, 2021 1:14pm
Whenever there's a barrier between a disease and the payors unwillingness to blindly pay for treatment, science steps in and creates innovative tests.  This will be the same.  Payors/Insurers will want something more failproof than a hunch and large wasteband in order to start treatement.  Less expensive testing can be done early to detect it before it gets to the worst case ...more  
Comment by scarlet1967 on Apr 03, 2021 1:44pm
Quite frankly if the science backs up set of accurate diagnostic sets which are more cost effective and less invasive it's a win win situation for all parties, patients get detected earlier thus less advanced symptoms, less pressure to the healthcare thus more resources to deal with othe conditions and less costs to payors as they don't need to cover lengthy and extensive treatment for ...more  
Comment by Wino115 on Apr 03, 2021 3:34pm
The negative to it all is that if you can develop a test with high accuracy and predictability that your liver is at the NAFLD or early NASH stage, likey the intervention would be diet, exercise and vitamin E (or whatever it is they tell you to take).  That will work for plenty of people and lower the percentage that get in to the NASH or advanced NASH stages.  That would be a far better ...more  
Comment by scarlet1967 on Apr 03, 2021 3:43pm
Hopefully early detection and prevention would work for as many as possible but from my own experience I know to convince people changing their habits it's easier said than done.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities